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A B S T R A C T
Introduction and aim: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid
organ and hematopoietic stem cell transplantation, associated with significant morbidity and mortality. In this
systematic review we evaluated the clinical performance of advanced imaging modalities at diagnosis and
treatment response evaluation of PTLD patients after solid organ and hematopoietic stem cell transplantation.
Methods: We have carried out a literature search until December 15, 2017 using PubMed/Medline, Embase,
“Web of Science” and Cochrane Library databases concerning the performance of computed tomography (CT),
magnetic resonance imaging (MRI) and 18F-flurodeoxyglucose positron emission tomography/computed tomo-
graphy (FDG-PET/CT) at diagnosis or treatment response evaluation of PTLD patients.
Results: A total of 11 studies were included comprising 368 patients, from which FDG-PET(/CT) was the primary
imaging modality investigated. The methodological quality according to QUADAS-2 of the reviewed studies was
moderate-poor. Subgroup analysis of imaging results for detection and staging in patients with PTLD indicated
that FDG-PET/(CT) identified additional lesions not detected by CT and/or MRI in 27.8%, (95% confidence
interval [95%CI]) 17.0%–42.0% (I2= 51.1%), from which extra-nodal sites in 23.6% (95%CI: 7.9%–52.4%)
(I2= 76.6%). False negative results occurred in 11.5% (95%CI: 4.9%–24.5%) (I2= 73.4%), predominantly in
physiological high background activity regions and in early PTLD lesions. False positive results occurred in 4.8%
(95%CI: 2.6%–8.6%) (I2= 0%) predominantly due to inflammatory conditions. Subgroup analysis of imaging
results at treatment response evaluation indicated that FDG-PET(/CT) findings altered or guided treatment in
29.0% (95%CI: 14.0%–50.5%) (I2= 40.1%). False positive results during treatment response evaluation were
reported in 20.0% (95%CI: 10.7%–34.2%) (I2= 0%), predominantly due to inflammatory conditions.
Conclusion: FDG-PET(/CT) is currently the most frequently investigated imaging modality in PTLD patients.
Available studies report promising results in detection, staging and therapy evaluation but suffer from metho-
dological shortcomings. Concerns remain with regard to occurrence of false negatives due to physiological high
background activity and early PTLD lesions as well as false positives due to inflammatory conditions.
https://doi.org/10.1016/j.critrevonc.2018.09.007
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Post-transplant lymphoproliferative disorder (PTLD) is a serious
complication after solid organ and hematopoietic stem cell transplan-
tation, associated with high morbidity and mortality. Although initially
reported as a rare complication of transplantation, PTLD incidence may
have been clinically underestimated (Maksten et al., 2016). While
lymphomas represent 4% of all cancers in an immunocompetent po-
pulation, they account for 21% of all cancer cases in transplant re-
cipients (Dierickx and Habermann, 2018). Incidence of PTLD may vary
from 1 to 20% depending on various risk factors such as pre-transplant
Epstein Barr virus (EBV) serology results, the degree of im-
munosuppression and the transplanted organ (Parker et al., 2010;
Singavi and Fenske, 2015). In allogeneic hematopoietic stem cell
transplantation, development of PTLD predominantly depends on the
degree of human leukocyte antigen mismatch along with aggressive T-
cell depletion methods (Landgren et al., 2009). PTLD encompasses a
wide morphologic spectrum ranging from EBV driven polyclonal pro-
liferation to highly aggressive monomorphic proliferations. Currently,
the World Health Organization (WHO) categorizes PTLD into: (i) non-
destructive lesions, (ii) polymorphic PTLD, (iii) monomorphic PTLD,
and (iv) classical Hodgkin lymphoma type PTLD (Swerdlow et al.,
2017). The most common is monomorphic PTLD, particularly diffuse
large B-cell lymphoma (DLBCL) (Bakker et al., 2007; Styczynski, 2017;
Mucha et al., 2010).
PTLD has an heterogeneous clinical presentation, which may re-
semble allograft dysfunction but may also be limited to nonspecific
symptoms such as weight loss, fever or malaise. At diagnosis, the
clinical spectrum ranges from a solitary asymptomatic process to a
fulminant systemic disease (Singavi and Fenske, 2015; Koffman et al.,
2000; Gottschalk et al., 2005). It may involve nodal and/or extra-nodal
sites, including the organ allograft or any other organ system (Singavi
and Fenske, 2015; Al-Mansour et al., 2013; Evens et al., 2010). PTLD
may develop at any time with a first peak incidence within one year
after transplantation and a second peak after 4–5 years (Bakker et al.,
2007; Végso et al., 2011; Camacho et al., 2014; Everly et al., 2007). A
variety of laboratory tests are routinely carried out to diagnose and
monitor disease progression. In case of EBV-positive PTLD, pre-emptive
treatment with rituximab is often initiated based on EBV DNA levels
and its change is routinely monitored during treatment. However, a
considerable limitation of this approach is the lack of standardized
cutoff values, monitoring time points and sampling source (Dierickx
and Habermann, 2018; Bakker et al., 2007; Styczynski, 2017). Although
EBV-associated PTLD is more clinically recognized, the incidence of
EBV-negative PTLD is often underestimated, comprising up to 50% of
PTLD cases (Blaes and Morrison, 2010; Trappe et al., 2012; Luskin
et al., 2015; Kinch et al., 2014). In light of such limitations, clinicians
cannot solely rely on EBV values to monitor disease progression/re-
gression. Upon suspicion of PTLD, a confirmatory biopsy provides es-
sential histopathological information. However, this is an invasive
procedure, may lead to complications and is not always possible for
deep-seated lesions close to vital structures (Parker et al., 2010;
Girometti et al., 2014).
Correct staging and accurate treatment response evaluation are
vital, as treatment and prognosis depend on these factors (Panagiotidis
et al., 2014). Considering the clinical characteristics of PTLD and the
limitations of current methods, advanced imaging modalities play a
crucial role at diagnosis and treatment response evaluation of PTLD
patients. Established imaging modalities include contrast-enhanced
computed tomography (CT) and magnetic resonance imaging (MRI),
relying mainly on morphological information. In recent years, 18F-
flurodeoxyglucose (FDG) positron emission tomography (PET) and in
particular hybrid FDG-PET/CT has gained clinical importance pro-
viding both functional and anatomic information.
This systematic review aims to provide an evidence-based guidance
on the clinical value of advanced imaging modalities, including CT, MRI
and FDG-PET/CT in patients with PTLD after solid organ and hemato-
poietic stem cell transplantation. The relevant literature was system-
atically reviewed with a focus on diagnosis and treatment response
evaluation of patients with PTLD. The advantages and limitations of
each individual imaging modality in the setting of PTLD are discussed.
Future perspectives and suggestions for further research are also ad-
dressed.
2. Research design & methods
2.1. Selection criteria
The “PRISMA Statement for Reporting Systematic Reviews and
Meta-Analysis” and its suggestions have served as template for this
systematic review (Liberati et al., 2009; Moher et al., 2010). A sys-
tematic online literature search was conducted on PubMed/Medline,
Embase, “Web of Science” with the search terms “lymphoproliferative
disease/disorder”, “organ transplant”, “computed tomography”, “mag-
netic resonance imaging” and “18F-FDG positron emission tomography”
(for the full list of search terms, see Appendix 1). Data obtained through
the database search until December 15, 2017 were used in this sys-
tematic review. Original articles concerning the performance of CT,
MRI, FDG-PET or FDG-PET/CT at diagnosis and/or treatment response
evaluation of PTLD after solid organ and hematopoietic stem cell
transplantation were included. PTLD was classified according to the
indications provided by the 2008 WHO classification: (i) early lesions,
(ii) polymorphic PTLD, (iii) monomorphic PTLD, and (iv) classical
Hodgkin lymphoma type PTLD (Swerdlow et al., 2008; Turner et al.,
2010; Tsao and Hsi, 2007; Taylor et al., 2005). Although the authors
acknowledge the existence of a revised version, the studies included in
this systematic review were carried out before the current classification
(Swerdlow et al., 2017). Both prospective and retrospective studies as
well as blinded or non-blinded studies were included. There were no
selection criteria based on a specific reference standard. Articles in
English were considered. We excluded case reports/small case series
(studies with less than 5 patients), pre-clinical studies, abstracts, con-
ferences reports and seminar reports.
2.2. Literature search
Duplicates from the various online search databases were elimi-
nated using Mendeley Desktop Version 1.1710 (Elsevier, Amsterdam,
Netherlands). The remaining articles were screened for title and ab-
stract. The selected articles were further evaluated in full-text for
eligibility based on the inclusion criteria. Additionally, the Cochrane
Library was searched for reviews on PTLD and crossed-checked refer-
ences with selected studies for other relevant articles. The authors of
the included studies were approached via email, when necessary, in an
attempt to clarify results and obtain quantitative data.
2.3. Methodological quality assessment
Methodological quality of the included studies was assessed ac-
cording to the “Quality Assessment of Diagnostic Accuracy Studies”
(QUADAS-2) (Whiting et al., 2011). The four main assessment cate-
gories of QUADAS-2 include: patient bias, index test bias, reference test
bias and flow and timing bias. CT, MRI or FDG-PET(/CT) were con-
sidered to be the index test. Although stand-alone FDG-PET studies
were included in our systematic review, this technique is considered an
outdated imaging modality and clinically inferior to FDG-PET/CT
(Adams and Kwee, 2016a). The use of stand-alone FDG-PET was scored
as high applicability concern. At diagnosis, histological confirmation of
PTLD was considered to be the reference standard. At end of treatment,
although histological confirmation was the preferred reference stan-
dard, biopsy is not always possible nor standardly requested by the
treating physician. In case histological sampling was not available,
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clinical follow-up for a minimum of 2 years and imaging was also ac-
cepted. The lack of a biopsy at treatment response evaluation may in-
fluence study bias, but not applicability to our review. A grading
guideline was tailored for this systematic review to aid quality assess-
ment (Appendix 2). For each category a quality grade was assigned
ranging between: high risk of bias, unclear risk of bias or low risk of
bias.
2.4. Statistical analysis
Pooled subgroup analyses were performed for mutual denominators
among the included studies. In the detection and staging sections these
were: detection of additional lesions, detection of extra-nodal lesions,
upstaging of patients, clarification of dubious lesions, false negative and
false positive results. In the treatment response evaluation section the
subgroups were: detection of additional lesions, early remission detec-
tion, influence on treatment course, additional guidance in therapy
monitoring, false negative results, false positive results and relapse after
complete remission according to FDG-PET(/CT). An I2 greater than 50%
was considered indicative of high inter-study heterogeneity (Higgins
et al., 2003). Weighted proportions with a 95% confidence interval (CI)
were calculated using a random effects model (I2> 50%) or a fixed
effects model (I2≤50%). Statistical analyses were executed using
Comprehensive Meta-Analysis Version 3 (Biostat, Englewood, Illinois,
USA).
3. Results
3.1. Selection of literature
After duplicate exclusion, a total of 4619 articles were identified
through an electronic database literature search (Fig. 1). After re-
viewing these articles for title and/or abstract, 27 FDG-PET(/CT), 16 CT
and 16 MRI articles remained. These were further analyzed in full-text.
Sixteen FDG-PET(/CT) articles were excluded: 5 reported results in less
than 5 patients, 3 articles included non-separable data from other
complications after organ transplantation, 5 were pictorial or
descriptive studies, in 2 articles PTLD was not the main focus of the
discussion and 1 article included histopathology results not concurrent
with the 2008 WHO classification of PTLD. In total, 11 FDG-PET(/CT)
articles were included in this review. Only 1 article on the diagnostic
performance of CT remained after full-text evaluation. The majority of
excluded articles did not provide any information regarding the per-
formance of CT in the evaluation of PTLD patients (n=11). Of the 4
remaining studies, 2 articles included histopathology results not con-
current with the 2008 WHO classification, 1 included less than 5 pa-
tients, and in 1 article data from other immunocompromised patients
could not be separated from PTLD. No article concerning MRI could be
included in this review. Five articles included less than 5 patients and
another 6 were pictorial or descriptive studies. The remaining 5 studies
did not provide any original data. In total, this review included 11
original research articles because 1 article reported the diagnostic
performance of both FDG-PET/CT and CT alone.
3.2. Methodological quality of included studies
The methodological quality of included studies according to
QUADAS-2 is displayed in Table 1 and Fig. 2. With regard to patient
selection, 4 studies had a high risk of bias and 6 high applicability
concerns. Concerns leading to high risk of bias classification included:
clinical diagnosis of PTLD in a significant number of patients and in-
appropriate exclusions. Applicability concerns were due to a narrow
study population. In the index test domain 7 studies scored unclear risk
of bias because these studies did not report if FDG-PET(/CT) was in-
terpreted in a blinded fashion and 1 study scored high risk of bias be-
cause of non-blinded interpretation. Seven studies had high applic-
ability concerns with regard to the index test. These studies either used
stand-alone FDG-PET in the evaluation of PTLD patients or outdated
interpretation criteria for FDG-PET(/CT) scans. With regard to the re-
ference standard, 9 studies scored high risk of bias because findings on
FDG-PET(/CT) were not systematically histologically confirmed either
at diagnosis or follow-up. High application concerns for reference index
were scored in 3 studies. In 2 studies, follow-up was less than 2 years
after the last FDG-PET(/CT) scan and in 1 study there was no clear
reference standard. Nine studies had high risk of bias with regard to
flow and timing. The main concerns were lack of baseline FDG-PET(/
CT) and inconsistent/lack of a reference standard.
3.3. Study characteristics
The 11 studies included in this systematic review compromised a
total of 368 patients. Each patient included in the review underwent at
least one FGD-PET(/CT) scan performed at diagnostic or treatment re-
sponse evaluation of PTLD (Table 2) (Panagiotidis et al., 2014; Blaes
et al., 2009; Zimmermann et al., 2018; von Falck et al., 2007; Dierickx
et al., 2013; Gheysens et al., 2016; Guerra-García et al., 2017; Bakker
et al., 2006; O’Conner and Franc, 2005; Takehana et al., 2014; Vali
et al., 2015). The age of participants ranged from 1 to 82 years. Three
studies used solely stand-alone FDG-PET, 4 studies used stand-alone
FDG-PET and FDG-PET/CT and 4 studies used exclusively FDG-PET/CT.
In the 269 histologically proven PTLD cases at diagnosis, the majority
of PTLD lesions were of the monomorphic subtype (n=215), followed
by polymorphic (n=24), early lesions (n=21) and classical Hodgkin
lymphoma type PTLD (n= 9). In the remaining cases, diagnosis of
PTLD was based on clinical findings or follow-up. The type of trans-
plantations most frequently performed in our study cohort were: kidney
(35%) followed by liver (19%), lung (15%), heart (13%), hematopoietic
stem cell transplantation (9%), multiorgan transplant (6%), small
bowel (2%) and pancreas (1%).
3.4. Role of imaging in detection and staging
Ten studies provided data about the diagnostic and stagingFig. 1. Study selection flow-chart.
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performance of FDG-PET(/CT) (Table 3) (Table 4) (Panagiotidis et al.,
2014; Blaes et al., 2009; von Falck et al., 2007; Dierickx et al., 2013;
Gheysens et al., 2016; Guerra-García et al., 2017; Bakker et al., 2006;
O’Conner and Franc, 2005; Takehana et al., 2014; Vali et al., 2015).
Pooled data from 7 studies showed that FDG-PET(/CT) identified ad-
ditional lesions in 27.8% (95%CI: 17.0%–42.0%) (I2= 51.1%) not de-
tected by morphological imaging (CT or MRI), from which extra-nodal
sites in 236% (95%CI: 7.9%–52.4%) (I2= 76.6%) (Panagiotidis et al.,
2014; Blaes et al., 2009; von Falck et al., 2007; Bakker et al., 2006;
Dierickx et al., 2013, 2013; Gheysens et al., 2016; Guerra-García et al.,
2017; Bakker et al., 2006; O’Conner and Franc, 2005; Takehana et al.,
2014; Vali et al., 2015). Based on 3 studies, FDG-PET/CT findings up-
staged patients compared to CT alone in 15.3% (95%CI: 9.0%–24.7%)
(I2= 100%). Data from 4 studies indicated that FDG-PET(/CT) was
used to clarify dubious lesions seen on morphological imaging in 29.1%
(95%CI: 7.5%–67.4%) (I2= 70.2%) (Panagiotidis et al., 2014; Blaes
et al., 2009; Takehana et al., 2014; Vali et al., 2015). Using available
data from 4 studies, it could be demonstrated that FDG-PET(/CT) failed
to detect histologically confirmed PTLD lesions in 11.5% (95%CI:
4.9%–24.5%) (I2= 73.4%) (Panagiotidis et al., 2014; Blaes et al., 2009;
Dierickx et al., 2013; Vali et al., 2015). These, particularly involved
regions of physiological high background activity, such as the brain,
kidneys or heart and early PTLD lesions. In a single study, CT detected
additional lesions not visualized on stand-alone FDG-PET in 7 cases
(Vali et al., 2015). Based on 2 studies, false positive results at staging
were observed in 4.8% (95%CI: 2.6%–8.6%) (I2= 702%), pre-
dominantly due to inflammatory conditions (Panagiotidis et al., 2014;
Dierickx et al., 2013). Data extracted from 2 studies indicated that
patient-based sensitivity of FDG-PET(/CT) varied between 88–89%,
specificity between 89–91%, positive predictive value (PPV) between
88–91% and negative predictive value (NPV) between 87–91%
(Panagiotidis et al., 2014; Dierickx et al., 2013). Concerning CT, Pa-
nagiotidis et al. found a sensitivity of 88%, specificity of 89%, PPV of
88% and NPV of 89% (Panagiotidis et al., 2014).
Gheysens et al. focused exclusively on the diagnostic performance of
FDG-PET/CT for the detection of bone marrow involvement in PTLD
patients compared to bone marrow biopsy (BMB). Although false-po-
sitive results could not be completely ruled out, FDG-PET/CT was re-
ported to have higher sensitivity than BMB in detecting bone marrow
involvement (Gheysens et al., 2016). These findings seem to be sup-
ported by other included studies, where FDG-PET(/CT) was an accurate
tool in detecting bone marrow lesions (Panagiotidis et al., 2014; von
Falck et al., 2007; O’Conner and Franc, 2005; Takehana et al., 2014;
Vali et al., 2015). The clinical value of the maximum standardized
uptake value (SUVmax) and its ability to distinguish between different
PTLD subtypes was also evaluated. Takehana et al. found a statistically
significant difference in the mean SUVmax between PTLD subtypes,
reporting a mean SUVmax for the monomorphic subtype of 10.9 versus
4.5 for the polymorphic type (Takehana et al., 2014). In the study by
Vali and colleagues, the mean SUVmax for monomorphic PTLD was 8.9,
while the values for polymorphic and early subtypes were 5.1 and 4.8,
respectively. However, this difference was not statistically significant
(Vali et al., 2015).
3.5. Role of imaging in treatment response evaluation
A total of 6 studies evaluated the performance of FDG-PET(/CT)
either at interim or end of treatment (Tables 5 and 6) (Blaes et al., 2009;
Table 1
Risk of bias in different domains according to the QUADAS-2.
Study (year) Risk of bias Applicability concerns
Patient selection Index test Reference standard Flow and Timing Patient selection Index test Reference standard
Bakker et al. (2006) Low Unclear High High High High Low
Blaes et al. (2009) Low Unclear High High Low High Low
von Falck et al. (2007) High Unclear High High High High High
Dierickx et al. (2013) High Low High High Low High Low
Gheysens et al. (2016) Low Low High High High Low High
Guerra-García et al. (2017) Low Unclear High High High Unclear Low
O’Conner and Franc (2005) Low Unclear High High High High Unclear
Panagiotidis et al.(2014) High High High High Low Low High
Takehana et al. (2014) Low Unclear Low Low Low Low Low
Vali et al. (2015) Low Low Low Low High High Low
Zimmermann et al. (2018) High Unclear High High Low High Low
Fig. 2. Risk of bias in different domains according to the QUADAS-2.
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Zimmermann et al., 2018; von Falck et al., 2007; Guerra-García et al.,
2017; Bakker et al., 2006; O’Conner and Franc, 2005). Pooled data from
3 studies showed that FDG-PET(/CT) detected additional lesions not
visualized by CT in 15.0% (95%CI: 5.7%–34.1%) (I2= 0%), leading to
intensification or continuation of treatment (Blaes et al., 2009; Guerra-
García et al., 2017; Bakker et al., 2006). Data from 3 studies indicated
that after initial treatment, lesions detected on CT were metabolic in-
active on FDG-PET(/CT) in 32.1% (95%CI: 15.9%–54.2%) (I2= 0%)
(von Falck et al., 2007; Guerra-García et al., 2017; Bakker et al., 2006).
In these studies, patients with inactive metabolic lesions on FDG-PET(/
CT) were considered to be in complete remission and treatment was
stopped in half of the cases to minimize treatment related complica-
tions. Patients in which treatment was stopped remained in complete
remission throughout study follow-up (Guerra-García et al., 2017;
Bakker et al., 2006). Based on 3 studies, findings from FDG-PET(/CT)
influenced treatment course in 29.0% (95%CI: 14.0%–50.5%)
(I2= 40.1%) (Blaes et al., 2009; Guerra-García et al., 2017; Bakker
et al., 2006). Furthermore, data from 3 studies indicated that FDG-
PET(/CT) provided additional support in therapy guidance in 13.5%
(95%CI: 4.3%–35.1%) (I2= 0%) by aiding the visualization of disease
progression/remission (Blaes et al., 2009; Guerra-García et al., 2017;
O’Conner and Franc, 2005). False negative results were reported in one
study, in a single case of central nervous system (CNS) involvement
(Guerra-García et al., 2017). Pooled data from 2 studies showed that
false positive results during treatment response evaluation occurred in
20.0% (95%CI: 10.7%–34.2%) (I2= 0%), predominantly due to in-
flammatory conditions. Based on 2 studies, 12.4% (95%CI:
5.2%–27.0%) (I2= 65.0%) of patients relapsed during study follow-up
after complete remission according to FDG-PET(/CT) scans.
In a 5-year follow-up study, Zimmerman et al. reported an end of
treatment FDG-PET(/CT) sensitivity of 71%, a specificity 73%, a PPV
38% and an NPV 92% for PTLD relapse. Additionally, a negative end of
treatment FDG-PET(/CT) was found to be a predictor of longer pro-
gression-free survival and longer time to progression (p=0.013 and
p=0.019) (Zimmermann et al., 2018). These findings were replicated
by Bakker et al., in which stand-alone FDG-PET was reported to be a
predictor of progression-free survival (Bakker et al., 2006).
4. Discussion
This systematic review and meta-analysis evaluated the clinical
performance of advanced imaging modalities in diagnosis and treat-
ment response evaluation of PTLD patients after solid organ and he-
matopoietic stem cell transplantation. In the selected studies, FDG-
Table 2





Mean age in years
(range)
Type of scan Histology at diagnosis Transplanted organ
Bakker 2006 12 NA Stand-alone FDG-
PET
NA 12 Kidney
Blaes, 2009 19 42 (3–65) Stand-alone FDG-
PET





































Gheysens, 2016 25 42 (6–76) FDG-PET/CT 21 Monomorphic PTLD (17 DLBCL, 2 plasmablastic

































Takehana 2014 30 24
(2–77)











Vali 2015 34 10 (4–17) Stand-alone FDG-
PET






















Abbreviations: CT computed tomography; DLBCL Diffuse large B-cell lymphoma; HSCT Hematopoietic stem cell transplantation; NA not available; PET 18 F-flur-
odeoxyglucose positron emission tomography; PTLD Post-transplant lymphoproliferative diseases.
* Results “Type of scan” and “Histology at diagnosis” per number of scans; results per patient not available.
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PET(/CT) identified at diagnosis additional metabolic foci not visua-
lized by morphological imaging in 27.8% (95%CI: 17.0%–42.0%)
(Panagiotidis et al., 2014; Blaes et al., 2009; von Falck et al., 2007;
Dierickx et al., 2013; Gheysens et al., 2016; Guerra-García et al., 2017;
Bakker et al., 2006; O’Conner and Franc, 2005; Takehana et al., 2014;
Vali et al., 2015). Detection performance was relatively high with re-
ported sensitivity values between 88%–89% and specificity between
89%–91%. Reported PPV and NPV values were as high as 91%
(Panagiotidis et al., 2014; Dierickx et al., 2013). Similar detection
performance of CT was reported by 1 reviewed study (Panagiotidis
et al., 2014). At treatment response evaluation FDG-PET(/CT) findings
altered or provided additional treatment guidance in 29.0% (95%CI:
14%–50.5%) (Blaes et al., 2009; von Falck et al., 2007; Guerra-García
et al., 2017; Bakker et al., 2006; O’Conner and Franc, 2005). End of
treatment FDG-PET(/CT) as a predictor for relapse had moderate sen-
sitivity of 71%, a moderate specificity 73%, but a satisfactory NPV of
92%. Finally, a negative end of treatment FDG-PET(/CT) was reported
to be a predictor of longer progression-free survival in 2 studies
(Zimmermann et al., 2018; Bakker et al., 2006).
Despite histopathologic similarities between PTLD and other lym-
phoid malignancies, direct extrapolation of research results from other
hematological malignancies is not possible as pathogenesis, clinical
presentation and management of PTLD differs significantly from that of
lymphomas seen in immunocompetent patients (Ganne et al., 2003).
Nonetheless, guidelines initially developed for staging and response
assessment of other lymphoid malignancies are commonly applied to
PTLD. In the evaluation of other FDG-avid lymphoproliferative malig-
nancies, FDG-PET/CT has become standard procedure, yet its role in
PTLD is less well defined (Cheson, 2015; Barrington et al., 2014;
Juweid, 2011).
The results from this systematic review indicate that FDG-PET(/CT)
plays an important role in diagnosis, staging and treatment response
evaluation of patients with PTLD. At diagnosis, accurate staging is
crucial as it determines extent of disease, prognosis and serves as a
baseline in treatment response evaluation. FDG-PET(/CT) detected
additional lesions not readily visualized by morphological imaging,
particularly extra-nodal lesions in 23.6% (95% CI: 7.9%–52.4%) of
cases (Panagiotidis et al., 2014; Bakker et al., 2006; Takehana et al.,
2014) (Fig. 3). Morphologic features may be nonspecific and the vi-
sualization of metabolic areas may be crucial in differentiating between
benign from malignant processes (Kwee et al., 2008; Juweid and
Cheson, 2005). Additional lesions detected by FDG-PET(/CT) may lead
to upstaging of disease and have a consequent clinical impact. Because
PTLD is characterized by an high incidence of extra-nodal involvement,
FDG-PET(/CT) may be more suitable than CT and/or MRI in diagnosis
and staging of these patients (Dierickx and Habermann, 2018;
Scarsbrook et al., 2005). Regarding treatment response evaluation,
FDG-PET(/CT) findings influenced treatment course in 29.0% (95% CI:
14.0%–50.5%), including cessation of treatment supported by meta-
bolic complete remission according to FDG-PET/CT (Blaes et al., 2009;
Guerra-García et al., 2017; Bakker et al., 2006). FDG-PET(/CT) may be
crucial in the visualization of metabolic inactive lesions and improve
treatment stratification decisions (Fig. 4). The current mainstay of
treatment for PTLD patients not responding to reduction of immune
suppression and/or initial rituximab therapy is R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisolone) as
second line treatment. Especially in patients with solid organ transplant
this is a highly toxic regimen, contributing to high treatment morbidity
and mortality (Singavi and Fenske, 2015; Dierickx et al., 2015; Choquet
et al., 2007; Elstrom et al., 2006). The treating physician is therefore
faced with the difficult decision of weighting treatment benefit against
the risk of treatment related complications. The results of this sys-
tematic review elucidate the value of FDG-PET(/CT) in therapy man-
agement with the potential to diminish treatment burden. Furthermore,
a negative FDG-PET(/CT) at end of treatment increases the likelihood
that PTLD is in clinical remission (NPV 92%) and patients may enter
standard clinical follow-up. On the other hand, considering the un-
satisfactory PPV, a positive FDG-PET(/CT) at the end of treatment may
require further diagnostic work-up (Zimmermann et al., 2018)
FDG-PET/CT has however certain drawbacks as the main imaging
modality. Regions of high background activity such as the brain,
myocardium, gastro-intestinal tract, bone marrow recovering from
chemotherapy and excretion of FDG through the urinary tract may
hinder an accurate diagnosis (Kwee et al., 2008; Yeung et al., 2003;
Lauro et al., 2015; Zukotynski et al., 2012). Caution is warranted in the
evaluation of heart, kidney and bowel transplant patients considering
that involvement of the transplanted organ occurs in up to 50% of PTLD
cases (Lopez-Ben et al., 2000; Opelz and Döhler, 2004). Another point
of concern is the high frequency of CNS involvement, which may occur
in 5–20% of PTLD cases (Dierickx and Habermann, 2018; Singavi and
Fenske, 2015; Caillard et al., 2006). Our review has demonstrated that
FDG-PET(/CT) is not accurate in detecting CNS lesions in PTLD pa-
tients, missing the diagnosis in multiple occasions (Blaes et al., 2009;
Dierickx et al., 2013; Guerra-Garcöa et al., 2017). These findings are
concurrent with current lymphoma and PTLD guidelines which re-
commend the use of MRI to assess suspicion of CNS involvement
(Parker et al., 2010; Barrington et al., 2014). In addition to areas of high
background activity, false negative results may also occur due the
limited spatial resolution of 6–7mm of the PET/CT camera system.
Although high-grade lymphomas are well visualized with FDG-PET/CT,
concerns still remain in low-grade histological subtypes (Elstrom et al.,
2003; Noraini et al., 2009). Given the histological variability of PTLD,
the diagnostic performance of FDG-PET/CT may be reduced in indolent
types. The results from our review indicate that while PTLD lesions
were generally FDG-avid, concerns still remain in early-lesion PTLD
(Panagiotidis et al., 2014; Dierickx et al., 2013).
FDG-PET/CT may also lead to false positive results due to in-
flammatory reactions. Concerns about the high incidence of false po-
sitive results with FDG-PET/CT are reported in other hematological
malignancies (Adams and Kwee, 2016a, b). Adams et al. have carried
out a systematic review and concluded that FDG-PET scans in patients
with lymphoma suffer from a high number of false positives during and
after treatment completion (Adams and Kwee, 2016a). According to the
author, proportion of false positives during and after treatment may
range between 7.7 and 90.5%, mainly due to inflammatory conditions.
This high rate of false positives may lead to unnecessary continuation of
highly toxic treatment, with high treatment-related mortality and an
increased chance of graft dysfunction and graft loss in transplant pa-
tients. In the reviewed cases, several results were reported as false
positives, mainly due to inflammatory conditions. However, due to the
lack of histological confirmation and lack of data, no firm conclusion
can be made about the incidence of FDG-PET/CT false positive results
Table 4









False negative False positive
Number of studies 7 3 3 5 4 2
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in PTLD patients. Although Zimmermann et al. and Panagiotidis et al.
have argued that false positive results may lead to the identification and
treatment of other potentially life threatening conditions, these may
also lead to invasive biopsies or other additional interventions with
associated complications (Panagiotidis et al., 2014; Zimmermann et al.,
2018).
5. Limitations
The heterogeneity of the reviewed studies makes direct comparison
challenging. Heterogeneity across the included studies must be taken
into consideration when interpreting the polled subgroup analyses. Six
out of the 12 subcategories were considered to have high inter-study
heterogeneity, particularly the subcategory “upstaging of patients”.
Population size and characteristics were heterogeneous across studies,
as well as methodology. Some studies used stand-alone FDG-PET as
their main imaging modality while others used FDG-PET/CT.
Additionally, acquisition methods for imaging modalities were often
partially described and varied per study group. Such details influence
diagnostic image quality and as result diagnostic accuracy.
Interpretation of FDG-PET(/CT) across studies was heterogeneous and/
or minimally described. The Deauville criteria are nowadays standardly
applied in treatment response evaluation of lymphomas, however sev-
eral studies included in this systematic review were carried out before
standardization occurred (Barrington et al., 2014). The methodology of
the reviewed studies was moderate-poor. Key concerns included: lack of
histological confirmation of suspected lesions (particularly at follow
up), inconsistent reference standard and the use of stand-alone FDG-
PET (Parker et al. (2010); Fueger et al. (2009)). The lack of histological
confirmation is also a major drawback in the reviewed studies. Con-
sidering the potential for false negative and false positive results with
FDG-PET/CT, a confirmatory biopsy would have strengthened the
conclusions drawn by the reviewed studies. Although it is clinically
accepted and understood that histological confirmation is not always
possible in clinical practice, its lack in this context, diminishes the de-
gree of certainty of the conclusions in the context of this systematic
review. Lastly, the lack of studies focusing on stand-alone CT or MRI for
diagnosis and treatment response evaluation in PTLD makes intermodal
comparison impossible.
6. Future perspectives
Although the importance of FDG-PET/CT is well established in the
field of hematological malignancies, this is not yet the case in PTLD
patients and international prospective studies are recommended to
compare the performance of the different imaging modalities.
Specifically, studies which evaluate the performance of FDG-PET/CT at
interim and end of treatment are lacking. These studies may ad-
ditionally evaluate the ability of FDG-PET/CT to improve risk stratifi-
cation of patients during treatment. Although no MRI studies were
Table 6
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I2-statistic 0% 0% 40.1% 0% – 0% 65.0%
Fig. 3. 78-year old patient with monomorphic
PTLD after kidney transplant. Maximum in-
tensity projection (MIP) of FDG-PET reveals
multiple metabolically active right cervical
lymphadenopathies, a focal lesion in the
omental foramen and a focal para-vertebral
lesion at the left side (left image). Transaxial
fused PET/CT of the pelvis shows a focal lesion
with increased FDG uptake at the left para-
vertebral area without noticeable lesion on CT
(right image).
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eligible for this review, it remains a potentially feasible imaging mod-
ality for the staging and treatment response evaluation of PTLD
(Schafer et al., 2014; Heacock et al., 2015; Afaq et al., 2017). In chil-
dren where ionizing radiation is a greater concern, MRI may be a valid
alternative to other imaging modalities. Particularly, the recent devel-
oped hybrid PET/MRI equipment is of great interest for this subgroup
with a significant reduction in ionizing radiation (up to 73%) (Schafer
et al., 2014; Heacock et al., 2015). Although some methodological is-
sues remain with regard to attenuation correction in osseous structures
and lungs, these may be solved in the near future, making PET/MRI a
valuable alternative for staging and treatment response evaluation of
lymphoma patients. To date, no reports have been published on the
applications of PET/MRI in PTLD patients. Another novel development
in the field of nuclear medicine is the use of targeted PET imaging. One
of the main limitations of FDG-PET/CT is its nonspecific character,
limiting differentiation between malignant lesions and other areas of
increased glucose uptake such as inflammatory or infectious foci. Cur-
rent studies indicate that targeted markers provide an attractive solu-
tion to this drawback. In pre-clinical studies, PARP1-targeted PET
imaging was superior to FDG-PET/CT in differentiating malignant le-
sions from inflammatory conditions in syngeneic DLBCL mouse models
(Tang et al., 2017). Additional research is also suggested on the role of
FDG-PET/CT in the detection of bone marrow involvement in PTLD.
Gheysens et al. suggested that FDG-PET/CT is an accurate tool to detect
focal marrow involvement and may obviate the need for a bone marrow
biopsy (Gheysens et al., 2016). Although some of the reviewed articles
seem to confirm this statement, the currently available data does not
permit a firm conclusion in this review (Panagiotidis et al., 2014; von
Falck et al., 2007; O’Conner and Franc, 2005; Takehana et al., 2014;
Vali et al., 2015). Finally, semi-quantitative measurements, ranging
from SUVmax and SUVpeak to high order metrics may provide valuable
clinical information and influence management in PTLD patients. Al-
though SUVmax and SUVpeak are clinically well recognized quantifi-
cation methods, large center studies are needed to precisely assert its
clinical value in hematological malignancies, specifically PTLD (Weber,
2005). More recently, whole-body metabolic metrics, such as metabolic
tumor volume (MTV) and total lesion glycolysis (TLG) have also been
suggested to better reflect tumor burden in lymphoma patients
(Berkowitz et al., 2008; Basu et al., 2014). In DLBCL patients, MTV has
been identified as a possible prognostic factor and as a tool to improve
risk stratification (Cottereau et al., 2016; Song et al., 2012). In another
study, TLG was found superior to the International Prognostic Index in
predicting overall survival and progression free survival in DLBCL pa-
tients treated with R-CHOP (Kim et al., 2013). Furthermore, the use of
machine-learning algorithms and its application in radiomics may in
the future enhance visual interpretation and pave the way to the de-
velopment of personalized medicine (Carlier and Bailly, 2015; Cook
et al., 2018).
Fig. 4. (A) 62-year old patient with monomorphic PTLD after kidney transplant. Baseline maximum intensity projection (MIP) of FDG-PET reveals multiple me-
tabolically active supra- and infra-diaphragmatic lymphadenopathies, multiple hyper-metabolic lesions in both lungs and a focal lesion in the left native kidney (left
image). Transaxial fused PET/CT and FDG-PET images of the thorax showing two focal lesions in the left lung and a focal lesion in the right lung (middle and right
image). (B) Patient after 8 cycles of rituximab. MIP FDG-PET reveals complete response (left image). Transaxial fused PET/CT and FDG-PET images show a remaining
focal lesion in the left lung without any remaining FDG activity corresponding to a complete response (middle and right image).
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7. Conclusions
At this moment, FDG-PET(/CT) is the most frequently used imaging
modality in PTLD patients after solid organ and hematopoietic stem cell
transplantation, showing promising results in the detection, staging and
therapy evaluation. However, the limited number of relatively small
studies with inherent methodological shortcomings prevents a firm
conclusion on this topic. When interpreting an FDG-PET(/CT) scan, one
must to be aware of eventual pitfalls, such as the occurrence of false
negatives due to physiological high background activity and early le-
sions PTLD (non-destructive PTLD, WHO 2017) as well as false positives
due to inflammatory conditions (Swerdlow et al., 2017). Although no
studies are available, MRI is the recommended imaging modality in
case of clinical suspicion of CNS involvement. Large multicenter pro-
spective studies using the available imaging modalities in an homo-
genous PTLD patient population are warranted to allow performance
comparison of advanced imaging modalities at diagnosis and treatment
response evaluation of PTLD patients.
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